ProCE Banner Activity

Selected FXR Agonist PBC Studies: Conference Coverage of AASLD

Conference Coverage
Podcast Episodes

Listen as Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses exciting new data from AASLD 2023 for people with PBC, including a study that evaluated real-world outcomes in patients treated with an FXR agonist as second-line therapy, lessons learned from PBC outcomes trials, and a late-breaking study of PBC treatment using an FXR agonist plus a fibrate.

Released: December 13, 2023

Share

Faculty

Kris V. Kowdley

Kris V. Kowdley, MD, FAASLD, FACP, FACG

Professor, Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from CymaBay Therapeutics.

CymaBay Therapeutics

Faculty Disclosure

Primary Author

Kris V. Kowdley, MD, FAASLD, FACP, FACG

Professor, Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington

Kris V. Kowdley, MD, FAASLD, FACP, FACG : consultant/advisor/speaker: 89Bio, AbbVie, BI, CymaBay, Genfit, Gilead, HighTide, Intercept, Ipsen, Kowa, Madrigal, Mirum, NGM NovoNordisk, Pliant, Pfizer, Terns, Zydus; researcher: 89Bio, Boston Pharma, Corcept, CymaBay, Genfit, Gilead, GlaxoSmithKline, Hanmi, HighTide, Intercept, Madrigal, Mirum, NGM, NovoNordisk, Pfizer, Pliant, Terns, Viking, Zydus; royalties or patent beneficiary: UpToDate.